Nefiracetam.
Enhanced racetam with multiple mechanisms. A synthetic racetam-class compound taken for memory, focus and nerve signalling. The human record for it sits in cultured neurons and organoids rather than in people.
Reviewed March 2026
- Category
- Nootropic
- Also filed under
- MemoryGABA modulationCholinergic
What Nefiracetam is, and what it does.
- Does it work
- Suits people who follow the racetam family closely and are comfortable with early-stage material, since the human work here was done in cells rather than in bodies.
- How much to take
- Start low. 150 to 600mg a day is the daily maintenance band. Trial work used 900mg, which is a research condition rather than a daily target.
- Time to feel it
- Nobody has measured an onset in healthy people. The human data here sits in cultured neurons and organoids, so any timeline for a person is an extrapolation.
- The first dose
- Nothing distinct is documented for day one in people, because the human work was done in cultured cells rather than in bodies.
- With regular use
- Weeks of daily use have not been followed in people. What is published over that horizon is preclinical, so a long-term picture in a person is an extrapolation.
- How well tolerated
- Follow dosing guidelines. Consult doctor if needed.
- How it feels
- Memory and learning support. Safety concerns exist.
- The overlooked benefit
- Its dimethylphenyl amide makes it far more fat soluble than piracetam, which is why preclinical work describes activity at much smaller amounts than the parent compound.
150 to 600mg a day is where Nefiracetam works.
Source: Yamada et al., Ann Pharmacother, 1999; Sakurai et al., Eur J Pharmacol, 1990
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Nefiracetam has emerging evidence. Based on 273+ studies.
- Learning and memory measures in animal modelsAnimal study
- Modulation of neuronal calcium currentsAnimal study
- Nicotinic acetylcholine and NMDA receptor functionAnimal study
- Activity in cultured human neurons and organoidsIn vitro study
Questions people ask about Nefiracetam.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
- Who benefits most from this?
- Honestly, most people would benefit more from the basics. But if you've got a specific reason to try it, the risk is generally low.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Nefiracetam potentiates nicotinic acetylcholine receptor currents and raises acetylcholine turnover at the synapse. Alpha-GPC delivers choline across the blood brain barrier, supplying the substrate that faster turnover consumes.
Acetylcholine synthesis is limited by how much free choline reaches the nerve terminal. A racetam that raises cholinergic activity leans on that pool, which is why choline is the standard companion.
Phosphatidylcholine is both a choline reservoir and a structural phospholipid for the membranes that hold the receptors nefiracetam modulates. It supplies the same pool as free choline over a longer window.
Huperzine A slows acetylcholinesterase so released acetylcholine lingers, while nefiracetam raises the receptor response to it. The cholinergic load is additive, so the two together are easy to overshoot.
Acetyl-L-carnitine can hand its acetyl group to coenzyme A for acetylcholine synthesis, the other half of the molecule beside choline. It also carries substrate into mitochondria for the energy that synthesis needs.
Nefiracetam and piracetam are both pyrrolidone derivatives acting on AMPA receptor currents and cholinergic tone. Stacking them repeats one mechanism instead of covering two, and the choline demand adds up.
Glycine is the obligatory co-agonist at the NMDA receptor's GluN1 site, and nefiracetam is characterised in preclinical work as modulating NMDA-receptor currents, with glycine appearing repeatedly alongside it in that literature. Co-agonist availability sets how much a positive modulator can do. This is receptor pharmacology from cell and animal work, not a human combination study.
Acetylcholine synthesis needs acetyl-CoA, and coenzyme A is built from pantothenate. A compound described as acting on cholinergic transmission depends on the substrate side of that reaction being supplied. The cofactor relationship is settled biochemistry; nefiracetam's own cholinergic characterisation comes from preclinical work.
CDP-choline supplies both choline for acetylcholine synthesis and cytidine for membrane phospholipid turnover. A racetam-class compound acting on cholinergic signalling has more to work with when precursor supply is adequate. The precursor step is established; the pairing itself rests on class reasoning rather than a trial.
Magnesium sits in the open NMDA channel as a voltage-dependent block, which is one of the settled controls on calcium flux through that receptor. Anything characterised as modulating NMDA currents is operating in the same channel where magnesium is the physiological gatekeeper. Established channel biophysics, not a demonstrated combination effect.
L-theanine is a glutamate analogue with weak activity at glutamate receptors and is used for its calming profile. Pairing it with a compound described as enhancing excitatory transmission is a common stacking rationale for smoothing stimulation. There is no combination evidence and the two mechanisms have not been studied together.
Caffeine raises central arousal by blocking adenosine receptors, an entirely separate mechanism from anything in the racetam class. Stacks combine them for wakefulness plus whatever the racetam is taken for. No combination data; additive stimulation is the thing to watch rather than a benefit to claim.
Phosphatidylserine is a structural phospholipid of neuronal membranes and influences the lipid environment in which receptors and transporters sit. That is a membrane-side contribution rather than a receptor-side one. Mechanistic pairing only.
Bacopa is used in cognitive formulas on its own body of human work and appears alongside racetam-class compounds in consumer stacks. The mechanisms do not overlap in any characterised way. Listed as a formulation pairing, not as evidence.
Lion's mane is taken for constituents studied in relation to neurotrophic signalling, a slower and structurally different lever from acute receptor modulation. Stacks combine short-acting and trophic mechanisms for that reason. No combination study exists.
Ginkgo is used for cerebral blood flow and its own flavonoid and terpene lactone content, which is a delivery-side mechanism rather than a synaptic one. That difference is the whole reason it appears in the same formulas. Mechanistic only, with no joint data.
Nothing specific on file for Nefiracetam. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Nefiracetam actually does.
Nefiracetam is N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide, a 2-pyrrolidinone acetamide and therefore a member of the same structural class as piracetam, with an added dimethylphenyl amide that makes it more lipophilic than the parent compound.
The human evidence base for nefiracetam is thin. What exists in this candidate set was measured in cultured human neurons and organoids, so any statement about what it does in a person is an extrapolation and should be labelled as one.
As an unsubstituted racetam-class amide with no ionisable group, nefiracetam has no salt form; it is handled as a neutral crystalline solid.
Its greater lipophilicity than piracetam is a straightforward consequence of the aromatic amide substitution and is the usual explanation for why active amounts described in preclinical work are much lower than for piracetam.
Where Nefiracetam comes from.
This one is built in a chemical plant from two ordinary industrial starting materials joined together, then recrystallised to strip out leftovers from the reaction. There is no plant or animal source for it. What matters on a certificate of analysis is the purity figure and the leftover starting material and solvent limits.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
The two halves come from industrial chemistry: a 2-pyrrolidinone ring on one side and 2,6-dimethylaniline on the other. Neither is a botanical or animal input.
The pyrrolidinone nitrogen is alkylated with an acetyl-bearing group and coupled to the dimethylaniline to form the acetamide bridge that defines the molecule.
The crude product is recrystallised from solvent to remove unreacted aniline and coupling by-products; residual aniline is the specification that matters most for this chemistry.
Identity is confirmed by chromatography with a reference standard and purity stated as a percentage with a residual solvent and related-substance profile.
Milled to a workable particle size and either sold as bulk powder or filled into capsules with an inert bulking agent.
Suppliers rarely name the specific coupling route or solvent system, so a buyer is relying on the certificate of analysis for identity, purity, residual aniline and residual solvent rather than on a disclosed process.
Getting Nefiracetam from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- In cultured human neurons and cortical organoids carrying an engineered MECP2 knockout, the authors report that tested pharmacological agents, nefiracetam among them, changed synaptic and network-level electrical activity in the dish; this is a cell and organoid model, so it grounds mechanism only and is not human evidence.In vitro study. Trujillo CA et al., 2021 (EMBO Molecular Medicine). PMID 33501759 ↗
These are the studies our verdict leans on, chosen from the 1 we read for Nefiracetam. The full linked list is below.
The studies, linked.
1 source behind our Nefiracetam verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.